Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1924152rdf:typepubmed:Citationlld:pubmed
pubmed-article:1924152lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:1924152lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:1924152lifeskim:mentionsumls-concept:C0047911lld:lifeskim
pubmed-article:1924152lifeskim:mentionsumls-concept:C0599473lld:lifeskim
pubmed-article:1924152pubmed:issue8lld:pubmed
pubmed-article:1924152pubmed:dateCreated1991-11-5lld:pubmed
pubmed-article:1924152pubmed:abstractTextReduced haloperidol (RHAL) is the best known metabolite of haloperidol (HAL), having been identified in humans, rats, and guinea pigs. Since RHAL contains an asymmetric center, it can exist in two possible enantiomeric forms. However, the enantiomeric composition of the RHAL formed from HAL in vivo has never been reported. As a first step toward the enantiomeric analysis of biological samples, we have developed an efficient and stereospecific synthesis of (+)- and (-)-RHAL from readily available commercial materials. We have also identified an enantioselective chromatographic method using a chiral HPLC stationary phase which can detect as little as 1% of either enantiomer in synthetic samples of RHAL enantiomers.lld:pubmed
pubmed-article:1924152pubmed:languageenglld:pubmed
pubmed-article:1924152pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1924152pubmed:citationSubsetIMlld:pubmed
pubmed-article:1924152pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1924152pubmed:statusMEDLINElld:pubmed
pubmed-article:1924152pubmed:monthAuglld:pubmed
pubmed-article:1924152pubmed:issn0724-8741lld:pubmed
pubmed-article:1924152pubmed:authorpubmed-author:WoodT ETElld:pubmed
pubmed-article:1924152pubmed:authorpubmed-author:PriebeSSlld:pubmed
pubmed-article:1924152pubmed:authorpubmed-author:KIDDR ARAlld:pubmed
pubmed-article:1924152pubmed:authorpubmed-author:CapratheB WBWlld:pubmed
pubmed-article:1924152pubmed:issnTypePrintlld:pubmed
pubmed-article:1924152pubmed:volume8lld:pubmed
pubmed-article:1924152pubmed:ownerNLMlld:pubmed
pubmed-article:1924152pubmed:authorsCompleteYlld:pubmed
pubmed-article:1924152pubmed:pagination1002-5lld:pubmed
pubmed-article:1924152pubmed:dateRevised2000-12-18lld:pubmed
pubmed-article:1924152pubmed:meshHeadingpubmed-meshheading:1924152-...lld:pubmed
pubmed-article:1924152pubmed:meshHeadingpubmed-meshheading:1924152-...lld:pubmed
pubmed-article:1924152pubmed:meshHeadingpubmed-meshheading:1924152-...lld:pubmed
pubmed-article:1924152pubmed:meshHeadingpubmed-meshheading:1924152-...lld:pubmed
pubmed-article:1924152pubmed:year1991lld:pubmed
pubmed-article:1924152pubmed:articleTitleSynthesis of the enantiomers of reduced haloperidol.lld:pubmed
pubmed-article:1924152pubmed:affiliationDepartment of Chemistry, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, Michigan 48105.lld:pubmed
pubmed-article:1924152pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1924152lld:pubmed